COVAX crosses milestone of 500 million donated doses shipped to 105 countries This link will open in a new window.
The WHO grants prequalification to Roche's treatment This link will open in a new window for patients with severe or critical COVID-19. The company also commits to providing the treatment at cost in low and middle-income countries and to not enforce any patent in those countries.
BioNTech introduces the first modular mRNA manufacturing facility This link will open in a new window to help improve vaccine production in Africa.
Moderna announces a commercial partnership with Adium Pharma This link will open in a new window to deliver Moderna's COVID-19 vaccine to 18 countries in Latin America.
The industry commits to supporting countries to turn vaccines into vaccinations, focusing on Three Priorities This link will open in a new window to urgently increase access to COVID-19: country readiness, equitable distribution and innovation.
The WHO issues conditional recommendation for the use of MSD's COVID-19 antiviral treatment This link will open in a new window in patients with non-severe COVID-19 at highest risk of hospitalization.
Kenya and Moderna sign a memorandum of understanding to establish its first mRNA manufacturing facility in Africa This link will open in a new window to produce 500 million vaccine doses per year.
Moderna pledges not to enforce its patents for COVID-19 vaccines on manufacturers in low and middle-income countries This link will open in a new window in the Gavi COVAX Advance Market Commitment (AMC).
Johnson & Johnson announces an agreement with Aspen This link will open in a new window, based in South Africa, marking the first COVID-19 vaccine to be manufactured and distributed by an African company.
WIPO's World Intellectual Property Report 2022 This link will open in a new window estimates that the social benefit of COVID-19 vaccines far exceed their private benefit.
Moderna announces a partnership with International AIDS Vaccine Initiative This link will open in a new window to employ mRNA technology to tackle HIV/AIDS, tuberculosis, antimicrobial-resistant infections and COVID-19.
COVID-19 cases surpass 500 million. Approximately 5 billion people have received at least one dose of COVID-19 vaccine This link will open in a new window.
The WHO recommends Pfizer's COVID-19 antiviral This link will open in a new window, Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospitalization.
Chatham House, in collaboration with African Centre for Disease Control, CEPI and IFPMA organize a roundtable discussion to examine COVID-19 lessons learned This link will open in a new window to prepare better for future pandemics.
Moderna announces an Omicron-containing booster candidate This link will open in a new window that demonstrates superior antibody response, opening the possibility for once-a-year COVID-19 boosters.
The Sanofi-GSK next-generation COVID-19 vaccine booster This link will open in a new window delivers strong immune response against variants of concern, including Omicron.
BioNTech announces the construction of its first mRNA vaccine manufacturing facility in Rwanda This link will open in a new window, and plans to set up additional factories in Senegal and South Africa.